Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 09, 2023

SELL
$57.89 - $64.73 $1 Million - $1.12 Million
-17,294 Reduced 26.87%
47,067 $2.73 Million
Q2 2023

Aug 01, 2023

BUY
$63.71 - $70.74 $21,661 - $24,051
340 Added 0.53%
64,361 $4.12 Million
Q1 2023

Apr 19, 2023

BUY
$65.71 - $74.53 $105,595 - $119,769
1,607 Added 2.57%
64,021 $4.44 Million
Q4 2022

Jan 30, 2023

BUY
$68.48 - $81.09 $62,316 - $73,791
910 Added 1.48%
62,414 $4.49 Million
Q3 2022

Nov 14, 2022

BUY
$0.13 - $76.84 $381 - $225,371
2,933 Added 5.01%
61,504 $4.37 Million
Q2 2022

Aug 15, 2022

BUY
$72.62 - $79.98 $778,195 - $857,065
10,716 Added 22.39%
58,571 $4.51 Million
Q3 2021

Nov 10, 2021

BUY
$59.17 - $69.31 $790,570 - $926,050
13,361 Added 38.73%
47,855 $2.83 Million
Q2 2021

Jul 29, 2021

SELL
$61.91 - $67.42 $75,158 - $81,847
-1,214 Reduced 3.4%
34,494 $2.31 Million
Q1 2021

Apr 29, 2021

BUY
$59.34 - $66.74 $51,329 - $57,730
865 Added 2.48%
35,708 $2.25 Million
Q4 2020

Feb 04, 2021

SELL
$57.74 - $65.43 $883,133 - $1 Million
-15,295 Reduced 30.51%
34,843 $2.26 Million
Q3 2020

Oct 20, 2020

BUY
$57.43 - $63.64 $79,885 - $88,523
1,391 Added 2.85%
50,138 $3.02 Million
Q2 2020

Aug 12, 2020

BUY
$54.82 - $64.09 $20,667 - $24,161
377 Added 0.78%
48,747 $2.87 Million
Q1 2020

Apr 21, 2020

BUY
$46.4 - $67.43 $2.24 Million - $3.26 Million
48,370 New
48,370 $2.82 Million
Q1 2019

May 01, 2019

SELL
$45.12 - $53.8 $1.77 Million - $2.11 Million
-39,170 Closed
0 $0
Q4 2018

Feb 12, 2019

BUY
$48.76 - $63.23 $286,465 - $371,476
5,875 Added 17.65%
39,170 $2.04 Million
Q3 2018

Oct 10, 2018

BUY
$55.19 - $62.25 $1.84 Million - $2.07 Million
33,295 New
33,295 $2.08 Million

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $113B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Oliver Luxxe Assets LLC Portfolio

Follow Oliver Luxxe Assets LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Oliver Luxxe Assets LLC, based on Form 13F filings with the SEC.

News

Stay updated on Oliver Luxxe Assets LLC with notifications on news.